Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Ryan Sun
Consulting or Advisory Role: Boehringer Ingelheim
Research Funding: Sanofi
Jason Willis
Honoraria: Cor2Ed
Kanwal P. Raghav
Consulting or Advisory Role: AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Seattle Genetics
Speakers' Bureau: Bayer
Research Funding: Bayer (Inst), Roche/Genentech (Inst), Guardant Health (Inst), Daiichi Sankyo/Astra Zeneca (Inst), HiberCell (Inst), Merck Serono (Inst)
Van K. Morris
Consulting or Advisory Role: Incyte, Boehringer Ingelheim, Axiom Healthcare Strategies, BioMedical Insights, Bicara Therapeutics
Research Funding: Bristol Myers Squibb (Inst), EMD Serono (Inst), Immatics, Pfizer (Inst), BioNTech (Inst), Bicara Therapeutics (Inst)
John P. Shen
Stock and Other Ownership Interests: Agios, Syndax
Consulting or Advisory Role: Engine Biosciences
Research Funding: Celsius Therapeutics
Eduardo Vilar
Consulting or Advisory Role: Janssen Research & Development, Recursion Pharmaceuticals, Guardant Health
Research Funding: Janssen Research & Development
Patents, Royalties, Other Intellectual Property: The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional), The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional)
Travel, Accommodations, Expenses: Janssen Research & Development
Marko Rehn
Employment: Amgen
Stock and Other Ownership Interests: Amgen
Agnes Ang
Employment: Amgen
Stock and Other Ownership Interests: Amgen (Inst)
Research Funding: Amgen
Teresa Troiani
Consulting or Advisory Role: BMS Italy, Novartis, Servier, Pfizer
Scott Kopetz
Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines
Consulting or Advisory Role: Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, EMD Serono, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, AbbVie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical
Research Funding: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo
No other potential conflicts of interest were reported.
留言 (0)